OncoMatch/Clinical Trials/NCT06151236
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Is NCT06151236 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination for merkel cell carcinoma.
Treatment: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination — The goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Tumor Agnostic
Disease stage
Required: Stage I (≥ 10 MM), IIA, IIB, III (AJCC (8th ed))
Excluded: Stage DISTANT METASTASES
AJCC (8th ed) clinical or pathological stage I (≥ 10 mm), IIA, or IIB or III disease
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior anti-PD-1, CTLA-4, PDL-1 or LAG 3 antibody exposure, or an agent directed to another stimulatory or co-inhibitory T-cell receptor for any disease
Cannot have received: chemotherapy
any chemotherapy or experimental local or systemic drug treatment
Lab requirements
Cardiac function
Uncontrolled cardiovascular disease or history of myocarditis; Troponin T (TnT) or I (TnI) >2 × institutional ULN
Uncontrolled cardiovascular disease or history of myocarditis; Troponin T (TnT) or I (TnI) >2 × institutional ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06151236 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, chemotherapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage I (≥ 10 MM) or IIA or IIB or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify